Cynata Therapeutics Limited Stock Performance

CYYNF Stock  USD 0.22  0.00  0.00%   
On a scale of 0 to 100, Cynata Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 0.0671, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cynata Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cynata Therapeutics is expected to be smaller as well. Please check Cynata Therapeutics' variance and kurtosis , to make a quick decision on whether Cynata Therapeutics' price patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Cynata Therapeutics Limited are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Cynata Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
  

Cynata Therapeutics Relative Risk vs. Return Landscape

If you would invest  15.00  in Cynata Therapeutics Limited on November 17, 2025 and sell it today you would earn a total of  7.00  from holding Cynata Therapeutics Limited or generate 46.67% return on investment over 90 days. Cynata Therapeutics Limited is currently producing 0.7292% returns and takes up 5.8333% volatility of returns over 90 trading days. Put another way, 52% of traded pink sheets are less volatile than Cynata, and 86% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Cynata Therapeutics is expected to generate 7.64 times more return on investment than the market. However, the company is 7.64 times more volatile than its market benchmark. It trades about 0.13 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Cynata Therapeutics Target Price Odds to finish over Current Price

The tendency of Cynata Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.22 90 days 0.22 
about 1.2
Based on a normal probability distribution, the odds of Cynata Therapeutics to move above the current price in 90 days from now is about 1.2 (This Cynata Therapeutics Limited probability density function shows the probability of Cynata Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Cynata Therapeutics has a beta of 0.0671 suggesting as returns on the market go up, Cynata Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cynata Therapeutics Limited will be expected to be much smaller as well. Moreover Cynata Therapeutics Limited has an alpha of 1.0718, implying that it can generate a 1.07 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Cynata Therapeutics Price Density   
       Price  

Predictive Modules for Cynata Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cynata Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.010.226.10
Details
Intrinsic
Valuation
LowRealHigh
0.010.206.08
Details

Cynata Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Cynata Therapeutics is not an exception. The market had few large corrections towards the Cynata Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cynata Therapeutics Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cynata Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.07
β
Beta against Dow Jones0.07
σ
Overall volatility
0.03
Ir
Information ratio 0.16

Cynata Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cynata Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cynata Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Cynata Therapeutics is way too risky over 90 days horizon
Cynata Therapeutics has some characteristics of a very speculative penny stock
Cynata Therapeutics appears to be risky and price may revert if volatility continues
Cynata Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 7.77 M. Net Loss for the year was (5.45 M) with profit before overhead, payroll, taxes, and interest of 7.77 M.
Cynata Therapeutics Limited has accumulated about 26.79 M in cash with (3.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19.
Roughly 15.0% of the company shares are held by company insiders

Cynata Therapeutics Fundamentals Growth

Cynata Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cynata Therapeutics, and Cynata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cynata Pink Sheet performance.

About Cynata Therapeutics Performance

By analyzing Cynata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cynata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cynata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cynata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Things to note about Cynata Therapeutics performance evaluation

Checking the ongoing alerts about Cynata Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cynata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cynata Therapeutics is way too risky over 90 days horizon
Cynata Therapeutics has some characteristics of a very speculative penny stock
Cynata Therapeutics appears to be risky and price may revert if volatility continues
Cynata Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 7.77 M. Net Loss for the year was (5.45 M) with profit before overhead, payroll, taxes, and interest of 7.77 M.
Cynata Therapeutics Limited has accumulated about 26.79 M in cash with (3.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19.
Roughly 15.0% of the company shares are held by company insiders
Evaluating Cynata Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Cynata Therapeutics' pink sheet performance include:
  • Analyzing Cynata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cynata Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Cynata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Cynata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cynata Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Cynata Therapeutics' pink sheet. These opinions can provide insight into Cynata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Cynata Therapeutics' pink sheet performance is not an exact science, and many factors can impact Cynata Therapeutics' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Cynata Pink Sheet analysis

When running Cynata Therapeutics' price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing